This novel modular approach provides a personalized, response-tailored instrument for the time- and cost-effective collection of symptom-burden focused quantitative data.
The strengths of this study include the longitudinal collection of POP body burdens and survey data in a cohort with exposures near the general population of the United States (Anderson et al. 2008) and the measurement of multiple exposures.
Not so, says Heather L. Mac Donald, the influential institute thinker who risks being stereotyped as a right-leaning academic curmudgeon in her new collection of essays, "The Burden of Bad Ideas: How Modern Intellectuals Misshape Our Society" (Ivan R. Dee).
CS can reduce the data collection burden of MRI sequences by a factor dependent on the ability of the data to be compressed in some domain.
Project managers and donors focussed on the need for additional indicators (e.g. community-based activities, supervision of new health workers), while providers focussed on the data collection burden of existing indicators and reporting mechanisms.
Explanations for this include the time-consuming nature of collecting outcomes, and the perception of data collection as a burden [ 11].
The Burdens have a collection of contemporary paintings and of contemporary wines.
We achieved substantial cost savings by automating the collection of regulatory information and moving this burden from investigators to the study coordinating center.
All outcome measures for residents with dementia involve the collection of observational data with no additional burden or discomfort to the participant; many of these measures are part of good end-of-life care.
This design reduced the burden of data collection of teachers, but it may also have reduced the ability of the trial to detect differences in the incidence of diarrhoea between each trial arm.
In order to ensure that new therapies for these rare and severe genetic diseases will be available, regulatory agencies sometimes accept premarket evidence from smaller treatment groups while shifting the burden for the collection of additional information to FDA Phase IV postmarket surveillance, as was reported in FDA News for Fabrezyme® for the treatment of Fabry disease.
